Effects of dimethyl fumarate on neuroprotection and immunomodulation by Philipp Albrecht et al.
RESEARCH Open Access
Effects of dimethyl fumarate on neuroprotection
and immunomodulation
Philipp Albrecht1, Imane Bouchachia1, Norbert Goebels1, Nadine Henke1, Harald H Hofstetter1, Andrea Issberner1,
Zsuzsa Kovacs1, Jan Lewerenz2, Dmitrij Lisak1, Pamela Maher3, Anne-Kathrin Mausberg1, Kim Quasthoff1,
Corinna Zimmermann1, Hans-Peter Hartung1 and Axel Methner1,4*
Abstract
Background: Neuronal degeneration in multiple sclerosis has been linked to oxidative stress. Dimethyl fumarate is
a promising novel oral therapeutic option shown to reduce disease activity and progression in patients with
relapsing-remitting multiple sclerosis. These effects are presumed to originate from a combination of
immunomodulatory and neuroprotective mechanisms. We aimed to clarify whether neuroprotective concentrations
of dimethyl fumarate have immunomodulatory effects.
Findings: We determined time- and concentration-dependent effects of dimethyl fumarate and its metabolite
monomethyl fumarate on viability in a model of endogenous neuronal oxidative stress and clarified the mechanism
of action by quantitating cellular glutathione content and recycling, nuclear translocation of transcription factors,
and the expression of antioxidant genes. We compared this with changes in the cytokine profiles released by
stimulated splenocytes measured by ELISPOT technology and analyzed the interactions between neuronal and
immune cells and neuronal function and viability in cell death assays and multi-electrode arrays. Our observations
show that dimethyl fumarate causes short-lived oxidative stress, which leads to increased levels and nuclear
localization of the transcription factor nuclear factor erythroid 2-related factor 2 and a subsequent increase in
glutathione synthesis and recycling in neuronal cells. Concentrations that were cytoprotective in neuronal cells had
no negative effects on viability of splenocytes but suppressed the production of proinflammatory cytokines in
cultures from C57BL/6 and SJL mice and had no effects on neuronal activity in multi-electrode arrays.
Conclusions: These results suggest that immunomodulatory concentrations of dimethyl fumarate can reduce
oxidative stress without altering neuronal network activity.
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Background
Chronic disability in multiple sclerosis (MS) is due to
neuronal degeneration, which is not amenable, or is in-
completely amenable to immunomodulatory therapy.
The mechanisms remain elusive, but there is accumulating
evidence that oxidative stress may play a key role [1-3].
Dimethyl fumarate (DMF) is a novel oral therapeutic
agent which reduces disease activity and progression in
patients with relapsing-remitting MS [4,5]. Previously
suggested immunomodulatory mechanisms of action of
DMF or its metabolite monomethyl fumarate (MMF) in-
clude inhibition of cytokine-induced nuclear transloca-
tion of the nuclear factor kappa B (NF-κB) [6], apoptosis
of stimulated T cells [7], and increased production of the
TH2 cytokines IL-4 and IL-5 in stimulated T cells,
whereas generation of the TH1 cytokine interferon
gamma (IFN-γ) [8] is supposed to remain unaffected.
DMF also activates the transcription factor Nrf2 (nuclear
factor erythroid 2-related factor 2), which binds to anti-
oxidant response elements in the promoters of protective
genes such as NADPH-quinone-oxidoreductase-1
(NQO1) [9] and heme-oxygenase-1 [10]. This ultimately
raises the levels of the important intracellular antioxidant
* Correspondence: axel.methner@gmail.com
1Department of Neurology, Heinrich-Heine-University Düsseldorf, Medical
Faculty, Düsseldorf 40225, Germany
4Neurologische Klinik der Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5,
D-40225, Düsseldorf 40225, Germany
Full list of author information is available at the end of the article
JOURNAL OF 
NEUROINFLAMMATION
© 2012 Albrecht et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Albrecht et al. Journal of Neuroinflammation 2012, 9:163
http://www.jneuroinflammation.com/content/9/1/163
glutathione [9,10]. However, short-term incubation with
DMF for 60 minutes decreases the glutathione content of
cortical primary cultures and OLN-93 cells [11,12].
Here, we first investigated the concentration and time
dependence of DMF-mediated protection in neuronal
cells using a model of endogenous oxidative stress, oxi-
dative glutamate toxicity, where extracellular glutamate
blocks the glutamate-cystine antiporter system Χc-. This
leads to deprivation of cystine and its reduced form cyst-
eine, the rate-limiting substrate for the synthesis of
glutathione. The subsequent glutathione depletion gives
rise to the accumulation of reactive oxygen species and
cell death by oxidative stress (recently reviewed [13]).
We show herein that neuroprotective concentrations of
DMF suppress cytokine production by splenocytes from
two different mouse strains without effecting apoptosis
and do not impact neuronal network activity studied
with dissociated cortical cultures grown on multi-
electrode arrays [14] which allows a highly sensitive and
reproducible assessment of network activity. Our results
suggest that low doses of DMF may promote cellular re-
sistance against oxidative stress and cause immunomo-




DMF and MMF (sodium salt) for all experiments were
obtained from Biogen Idec, Carl-Zeiss-Ring 6 85737
Ismaning, Germany and solubilized in dimethylsulfoxide
(DMSO), which was also used as the vehicle control. The
pH of all media was kept constant at 7.4. Cell culture
dishes were from Greiner Bio-One, Maybachstraße 2.,
72636 Frickenhausen, Germany; DMEM cell culture
medium, sterile phosphate buffered saline were from
PAA, Unterm Bornrain 2, 35091 Cölbe, Germany; peni-
cillin, streptomycin were from Gibco/Life Technologies,
Frankfurter Straße 129B, 64293 Darmstadt, Germany;
cryopreserved primary dissociated cortical cultures from
embryonic rats were from QBM Cell Science Inc., 1200
Montreal Road, Building M23A, Suite 147, Ottawa, On-
tario, Canada; Cell Titer Blue was from Promega,
Schildkrötstraße 15 68199 Mannheim, Germany; the
high contact imaging microscope, the anti-CD3 antibody,
7-AAD and Annexin V PE were from Becton Dickinson,
Tullastr. 8-12, 69126 Heidelberg, Germany; the anti-Nrf2
antibody was from Santa Cruz Biotechnology, Berghei-
mer Straße 89, 69115 Heidelberg, Germany; the anti-
Actin antibody and secondary antibodies were from
Millipore, 290 Concord Road Billerica, MA 01821, USA;
the anti-NF-κB-antibody was from Cell Signaling Tech-
nologies, 3 Trask Lane Danvers, MA 01923, USA; multi-
electrode arrays were from Multichannel Systems,
Aspenhaustrasse 21. 72770 Reutlingen, Germany; the
MEA analyzing software Spanner was from RESULT soft-
ware, 47918 Tönisvorst, Germany; the Universal Probe
LibraryTM was from Roche, Emil-Barell-Str. 1 79639
Grenzach-Wyhlen, Germany; Fam-Tamra labeled oligo-
nucleotides were from Eurofins-MWG-Operon, Anzin-
gerstr. 7a, 85560 Ebersberg, Germany; the TNFα ELISA
was from R&D Systems, Borsigstrasse 7. 65205 Wies-
baden, Germany; the Immunospot Analyzer was from
CTL, 2860 Fisher Road, Columbus, OH 43204, USA;
Prism software was from GraphPad Software, 2236 Ave-
nida de la Playa, La Jolla, CA 92037, USA; spreadsheet
software was from Microsoft, Konrad-Zuse-Str. 1, 85716
Unterschleißheim, Germany; all other chemicals were
from Sigma Aldrich, Georg-Heyken-Str. 14 D-21147
Hamburg Germany.
Cell culture, viability assays and glutathione
measurement
The preparation of embryonic primary cortical cultures
and splenocyte cultures from C57BL/6 and SJL mice and
the cell culture of HT22 and fibroblast cells were per-
formed as described [15,16]. For the analysis of network
activity, cryopreserved primary dissociated cortical cul-
tures from embryonic rats (embryonic day 18, E18,
QBM Cell Science) were employed. After thawing, the
cells were plated at a final density of 105 cells on PDL-
/laminin-coated multi-electrode arrays (MEAs) or cover-
slips. Neuronal cultures were incubated in a humidified
atmosphere (5% CO2/95% air) at 37 °C for 24 h in DMF
or vehicle prior to glutamate treatment. Viability was
quantitated 24 h after glutamate addition by the Cell
Titer Blue (CTB) assay (Promega) and normalized to ve-
hicle treatment. Total glutathione was measured enzy-
matically as described previously [15] and normalized to
cellular protein measured by the bicinchoninic acid-
based method (Pierce). Glutathione released into the cell
culture medium was also quantitated enzymatically after
4 h in cystine-free medium and normalized to total cel-
lular protein. Cell viability of splenocytes was assessed
using flow cytometry quantitating 7-AAD (BD Pharmin-
gen #51-68981E) and Annexin V PE (BD Pharmingen
#556421) stained cells according to manufacturers’
protocols.
Cell fractionation, SDS-PAGE and immunoblotting
Differential detergent fractionation and immunoblotting
were performed as previously described [15] using anti-
Nrf2 (1:1000; Santa Cruz Biotechnology; #SC13032) and
anti-Actin (1:3000; Millipore, MAB1501) antibodies.
Translocation analysis of NF-κB and Nrf2
Intracellular localization of transcription factors was
quantitated by high-content imaging using a BD Pathway
855 microscope (BD Biosciences). HT22 cells were fixed
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with 4% paraformaldehyde and permeabilized with 0.3%
Triton-X 100, blocked with Roti ImmunoBlock (Roth
#144.1) for 1 h before they were incubated with primary
antibodies (NF-κB: Cell Signaling #9936 S, Nrf2: Santa
Cruz #sc-13032) overnight and stained with secondary
fluorochrome-labeled antibodies (Millipore #AP132F and
#124 F). Fluorescence intensities in regions of interest
defined by the nuclear stain DAPI (150 nM) were com-
pared with those of a second concentric band surround-
ing the nuclei and corresponding to the cytoplasm.
Quantitative real-time PCR
RNA extraction, reverse transcription and quantitative
real-time PCR were performed as previously described
[15] using Fam/Dark-quencher probes from the Univer-
sal Probe LibraryTM (Roche) or individually designed
Fam/Tamra probes (MWG). Beta-actin and HPRT served
as endogenous control genes and showed no differential
expression after incubation with DMF. Primer and probe
sequences can be obtained from the authors.
TNFα ELISA
Primary splenocytes from 6- to 8-week old female
C57BL/6 and SJL mice were stimulated with 1 μg/ml
anti-CD3 (BD Bioscience) and treated with 1, 10 and
100 μM of DMF. Supernatants were collected after 48 h
and concentration of TNFα was measured following the
manufacturer’s protocol (R&D Systems).
Cytokine enzyme-linked immunosorbent spot (ELISPOT)
assays
ELISPOT assays were essentially performed as previously
described [16] using splenocytes from 6- to 8-week old fe-
male C57BL/6 and SJL mice. Splenocytes were incubated
with 10 μM DMF or vehicle for 24 h while stimulated
with 0.5 μg/ml anti-mouse CD3. Computerized ELISPOT
analysis was done using an Immunospot Analyzer (CTL).
Extracellular microelectrode recordings and signal
analysis
Extracellular microelectrode recordings and signal ana-
lysis were performed as described [14]. Network activity
was recorded on multi-electrode arrays (MEAs) (Multi
Channel Systems) with 64 titanium nitride electrodes
(30 μm diameter and 200 μm spacing) at 37 °C using
sterile conditions. Signals from all 64 electrodes were
simultaneously sampled at 25 kHz, visualized and stored
using the standard software MC-Rack (Multi Channel
Systems). Spike and burst detection was performed off-
line using specialized software (SPANNER 2.0, Result,
Germany).
Statistical analysis
Statistical analysis was performed using spreadsheet
(Microsoft Excel) and Prism (Graphpad) software. Mul-
tiple group analyses were conducted using two-way
analysis of variance (ANOVA) and Bonferroni or Dun-
nett’s post hoc test, and comparison of two groups
using the two-tailed t-test. P-values< 0.05 were consid-
ered significant.
Results
DMF protects cells from oxidative stress by enhancing
Nrf2 abundance and nuclear translocation in a time- and
concentration-dependent manner
Pre-incubation with 10 μM DMF, but not MMF, for 24 h
protected primary cortical cultures and hippocampal
HT22 cells from oxidative glutamate toxicity (Figure 1A)
in line with the increase in cellular glutathione levels
seen in both the absence and presence of glutamate
(Figure 1B). The protective effect was concentration-
dependent for DMF (Figure 1C), but not for MMF at
24 h (Figure 1D). MMF protection took longer to de-
velop and only became evident after incubation for 96 h
(Figure 1E), whereas the effect of DMF was already max-
imal at 24 h (Figure 1F). When added together with glu-
tamate, DMF exacerbated toxicity (Figure 1F) in line
with the observation that DMF alone reduced cellular
glutathione already after a 1 h exposure (Figure 1G).
The transcription factor Nrf2 plays a key role in regulat-
ing the expression of proteins involved in GSH metabol-
ism. DMF increased Nrf2 protein abundance at
concentrations below 10 μM as shown by immunoblot-
ting of nuclear fractions (Figure 1H) and nuclear
localization as shown by immunocytochemistry after
24 h of 10 μM DMF treatment (Figure 1I). The previ-
ously reported [17] inhibition of NF-κB translocation to
the nucleus by DMF was not evident in these cells. In
addition, TNFα, which served as a positive control,
induced nuclear translocation of NF-κB, which was not
blocked by DMF (Figure 1J). This suggested that the
protective effect of DMF in these cells is mainly
mediated via the Nrf2-glutathione pathway. In line with
this, we observed no increase in glutathione content in
response to DMF in fibroblasts lacking Nrf2 (Figure 1K).
DMF protection involves glutathione recycling
DMF increased the mRNA abundance of various genes
involved in the antioxidant response in HT22 cells in-
cluding the enzymes glutamate-cysteine ligase (GCLC),
NQO1, and peroxiredoxin 1, as well as the system Χc-
subunit xCT while glutathione S-transferase 1 and
heme-oxygenase 1 were downregulated. In primary cor-
tical cultures, only xCT and NQO1 were upregulated by
DMF (Figure 2A). We then asked whether inhibition of
the function of the most upregulated transcripts, xCT
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Figure 1 Dimethyl fumarate (DMF) protects from oxidative stress by enhancing nuclear factor erythroid 2-related factor 2 (Nrf2)
abundance and translocation to the nucleus in a time- and concentration-dependent manner. A) DMF protects from oxidative glutamate
toxicity, a model of endogenous oxidative stress where extracellular glutamate blocks the cystine import ultimately causing glutathione (GSH)
depletion and cell death. Primary cortical cultures or hippocampal HT22 cells were preincubated with 10 μM DMF, monomethylfumarate (MMF)
or vehicle for 24 h and exposed to the indicated concentrations of glutamate for 24 h before cell viability was measured by the Cell Titer Blue
(CTB) assay. B) DMF and MMF increase cellular GSH concentrations. HT22 cells were treated with 10 μM DMF, MMF or vehicle for 24 h and
exposed to the indicated concentrations of glutamate for 8 h before intracellular glutathione was measured enzymatically. C-F) Dose and
time-course of DMF and MMF effect on oxidative glutamate toxicity. HT22 cells were treated for the indicated times and concentrations with
DMF, MMF or vehicle before addition of glutamate. Viability was quantitated 24 h later as described above. G) Time course of DMF effects on
glutathione content. HT22 cells were incubated with 10 μM DMF for the indicated periods of time before intracellular glutathione was measured
enzymatically. H) DMF enhances Nrf2 abundance quantitated by immunoblots done on nuclear fractions from HT22 cells treated with the
indicated concentrations of DMF for 4 h. I) and J) DMF induces nuclear localization of Nrf2 but has no effect on the nuclear translocation of
NF-κB as shown by high content imaging. I) HT22 cells were treated with vehicle (n = 9,561 cells), 10 μM DMF for 24 h (n = 8,170 cells) or with
25 μM TBHQ (n = 3,281 cells) as positive control for 4 h. J) HT22 cells were treated with vehicle or 10 ng/ml TNFα in the presence or absence of
10 μM DMF (vehicle n = 1,048 cells, DMF n = 943 cells, TNFα n= 1,410 cells, DMF+ TNFα n= 1,085 cells). Cells were fixed, stained and nuclear
localization analyzed by immunocytochemistry. K) DMF has no effect on GSH levels in fibroblasts derived from Nrf2-deficient mice. Cells were
treated with 10 μM DMF (black bars) or vehicle (white bars) for 24 h before GSH was measured enzymatically. Graphs of all experiments represent
the means ± standard error of the mean (SEM) of three independent experiments performed in triplicate. *P< 0.05, two-way ANOVA with
Bonferroni post hoc test in A), B), G), I), J), and paired Student’s t-test in K).
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and GCLC with S4-CPG and buthionine sulfoximine
(BSO), respectively, abolished the protective activity of
DMF. However, DMF was capable of protecting against
both compounds (Figure 2B). DMF was also still able to
raise glutathione levels when GCLC was inhibited or
when system Χc- activity was abrogated by incubation in
cysteine-free medium (Figure 2C). Therefore, DMF can
still exert protection in neuronal cells when de novo
glutathione synthesis is blocked, suggesting that it
enhances glutathione recycling.
Neuroprotective concentrations of DMF suppress cytokine
production in activated splenocytes from two different
mouse strains without exerting effects on viability
We then assessed the effects of 10 μM DMF, which was
clearly neuroprotective, on the viability and immune re-
sponse of primary mouse splenocytes isolated from
C57BL6 and SJL mice. Apoptosis was quantitated by flow
cytometry using Annexin V translocation and cell death
by 7-AAD staining. While 100 μM DMF increased dead
and apoptotic cells in both strains, the effects of 10 μM
were indistinguishable from DMSO, which was used as
the vehicle control (Figure 3A for C57BL6 mice and 3A’
for SJL mice). Having established that neuroprotective
concentrations of DMF were not harmful to primary
splenocytes, we then quantitated TNFα production in re-
sponse to stimulation with 1 μg/ml anti-CD3 for 48 h.
Here, 10 μM DMF attenuated TNFα production in
C57BL6-derived splenocytes (Figure 3B) and completely
abolished it in SJL-derived splenocytes (Figure 3B’). We
also analyzed direct changes in cytokine production in re-
sponse to anti-CD3 stimulation (0.5 μg/ml for 24 h) with
10 μM DMF or vehicle using ELISPOT technology. This
showed a significantly reduced production of IL-2 and
IL-17, but no changes in IL-4 and IL-5 in C57BL6 spleno-
cytes (Figure 3C) and a reduction in IL-2, IL-4, IL-5, IL-6,
and IL-17 production in SJL splenocytes (Figure 3C’).
These data suggest that neuroprotective concentrations
of DMF have a prominent immunomodulatory activity,
which is more pronounced in the more immune-

































































































Figure 2 Dimethyl fumarate (DMF)-mediated protection in
neuronal cells involves glutathione recycling. A) DMF treatment
induces mRNA expression of transcripts involved in the antioxidant
response. Cells were treated for 24 h with 10 μM DMF or vehicle
and mRNA quantitated by real-time PCR using β-actin and hprt as
endogenous controls. B) DMF protects from inhibition of GCLC by
BSO and inhibition of system Χc− by (S)-4- carboxyphenylglycine
(s-4-CPG). HT22 cells were treated for 24 h with 10 μM DMF or
vehicle and exposed to the indicated concentrations of s-4-CPG or
BSO for another 24 h before cell viability was measured by the CTB
assay. C) DMF still elevates cellular GSH when GSH synthesis is
blocked by GCLC inhibition by BSO or system Χc− inhibition by
incubation in cystine-free medium. HT22 cells were treated for 24 h
with 10 μM DMF (black bars) or vehicle (white bars) and then
exposed to the indicated concentrations of BSO or to cystine-free
medium for another 24 or 4 h respectively before intracellular GSH
was measured enzymatically. Graphs of all experiments represent
the means ± standard error of the mean (SEM) of three independent
experiments performed in triplicate.*P< 0.05, paired Student’s t-test.
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DMF-treated neuronal cells but not splenocytes secrete
neuroprotective GSH
Pretreatment with 10 μM DMF for 24 h increased the
GSH content in both HT22 cells and splenocytes to a
similar degree. However, DMF maintained the increase
in GSH in cystine-free medium only in HT22 cells but
not in splenocytes suggesting differences in GSH secre-
tion or recycling (Figure 4A). We further sought to de-
termine whether these DMF-mediated changes in GSH
content and viability of neuronal cells alter the viability
of splenocytes and vice versa. HT22 cells and spleno-
cytes were treated with 10 μM DMF or vehicle for 24 h.
DMF was then removed and the cells were incubated in
DMF-free medium to allow accumulation of secreted
GSH (or other DMF-induced secreted substances) for
another 24 h followed by transfer of the conditioned
medium to untreated cultures for an additional 24 h.
The medium conditioned by DMF-pretreated HT22 cells
elevated total cellular GSH in new HT22 cells while the
medium preconditioned by DMF-pretreated splenocytes
did not (Figure 4B). Furthermore, medium precondi-
tioned by DMF-pretreated HT22 cells also protected
new HT22 cells from oxidative glutamate toxicity
(Figure 4C) but had no effect on the viability of un-
stimulated splenocytes (Figure 4D). It was not possible
to do the reverse experiment using DMF-preconditioned
splenocyte medium on HT22 cells, as the oxidative-
glutamate-toxicity assay does not work in splenocyte
medium.
These data suggest that while both neuronal and im-
mune cells raise intracellular GSH levels upon DMF
treatment, only neuronal cells secrete this GSH into the
extracellular space where it can protect other neuronal



























































































































Figure 3 Neuroprotective concentrations of dimethyl fumarate (DMF) suppress cytokine production in activated splenocytes from two
different mouse strains without altering viability. 10 μM DMF does not significantly affect cell viability of splenocytes from C57BL/6 mice (A)
or SJL mice (A’) while 100 μM is toxic (A) and (A’). Cells were treated for 24 h with the indicated concentrations of DMF or vehicle. Cell viability
was measured by flow cytometry quantitating 7-AAD and Annexin V-positive cells. B) and B’) DMF concentration-dependently reduced TNFα
production from anti-CD3-stimulated splenocytes from C57BL/6 (B) and SJL mice (B’). Primary splenocytes from seven mice were treated with the
indicated concentrations of DMF for 48 h and co-stimulated with 1 μg/ml anti-CD3 for the same time before TNFα was measured in the
supernatants by ELISA. C) and C’) DMF decreases anti-CD3-induced production of IL-17 and IL-2 in splenocytes from C57BL/6 mice (C) and of the
production of IF-γ, IL-2, IL-4, IL-5, IL-6 and IL-17 in splenocytes from SJL mice (C’). Primary splenocytes from seven mice were treated with 10 μM
of DMF for 24 h and costimulated with 0.5 μg/ml anti-CD3 for the same time before interferon-gamma, IL-2, IL-4, IL-5, IL-6 and IL-17 were
measured using ELISPOT technology. Graphs of all experiments represent the means ± standard error of the mean (SEM) of three independent
experiments performed in triplicate.*P< 0.05, paired Student’s t-test in (C) and (C’) and two-way analysis of variance (ANOVA) with Bonferroni post
hoc test in (A), (A), (B), and (B’).
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not benefit from GSH released by neuronal cells, at least
under the conditions employed here.
No effect of DMF on the network activity of primary
dissociated cortical cultures grown on multi-electrode
arrays
MEAs allow a highly sensitive and reproducible assess-
ment of network activity by culturing dissociated cortical
cells directly on-chip (Figure 5A). In these cultures, spon-
taneous electrical activity and signal propagation of evolv-
ing neuronal networks can be observed non-invasively in
real time at 64 electrodes embedded into the chip. After
three weeks in vitro, networks exhibit regular bursting ac-
tivity consisting of single spikes or bursts, which can be
measured quantitatively by the spike and burst rate per
minute and the inter-burst interval (Figure 5B) [14,18].
Mature neuronal cultures derived from dissociated cor-
tical cells exhibited highly synchronous network activity
on MEAs (Figure 5C left panel), but incubation with 10
or 100 μM DMF for 30 sec, 1 h or 24 h did not change
the spike or burst frequency, inter-burst interval or syn-
chronicity of these cultures (Figure 5D). We conclude
that even excessive concentrations of DMF have no effect
on neuronal network activity measured with MEAs.
Discussion
Our main finding is that DMF at low concentrations
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Figure 4 Dimethyl fumarate (DMF)-treated neuronal cells but not splenocytes secrete neuroprotective glutathione (GSH). A) HT22 cells
and splenocytes show increased intracellular glutathione after 24 h pretreatment with 10 μM DMF, but only HT22 cells release glutathione into
the extracellular space. GSH was quantitated enzymatically and normalized to cellular protein content and vehicle-treated cells, respectively.
Released GSH in the medium was quantitated after 4 h incubation in cystine-free medium following a 24 h incubation in medium supplemented
with 10 μM DMF (black bars) or vehicle (white bars). B) HT22 cells treated with conditioned medium (CM) from HT22 cells but not splenocytes
take up released GSH and C) are protected from glutamate toxicity. HT22 cells were treated for 24 h with conditioned medium before addition of
the indicated concentrations of glutamate for another 24 h. Viability was quantitated by the CTB assay. (D) Viability of unstimulated splenocytes
quantitated by flow cytometry using Annexin V and 7AAD staining is unaffected by HT22 conditioned medium. Graphs of all experiments
represent the means ± standard error of the mean (SEM) of three independent experiments performed in triplicate. *P< 0.05, paired Student’s t-
test for all assays except two-way analysis of variance (ANOVA) with Bonferroni post hoc test for (C)..
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cellular glutathione, and that similar concentrations also
reduce production of proinflammatory cytokines from
splenocytes. In our experiments, DMF protection needed
less time to develop than protection induced by MMF.
The induction of the antioxidant response leading to
glutathione synthesis seems to be the consequence of an
initial and short-lived oxidative stress, since DMF
decreased the glutathione content immediately after its
addition to the cells. Most likely DMF as an unsaturated
carboxylic acid ester initially binds and sequesters gluta-
thione [19]. The long-term effect of DMF in neuronal
cells is most probably mediated via Nrf2 as other
reported mechanisms such as the inhibition of the nu-
clear translocation of NF-κB [19] were not evident in
these cells and because the increase in GSH synthesis
was abolished in cells lacking Nrf2.
On the mRNA level, the most prominently upregu-
lated transcript in HT22 cells and primary cortical cul-
tures was xCT, the functional subunit of system Χc-,
which is tightly involved in glutathione homeostasis
(reviewed in [13]). DMF, however, also raised the gluta-
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Figure 5 No effect of dimethyl fumarate (DMF) on the network activity of primary dissociated cortical cultures grown on multi-
electrode arrays (MEAs). A) Dissociated cortical cultures were grown on multi-electrode arrays and visualized by phase-contrast microscopy.
Black discs correspond to electrodes. B) Typical trace recorded from one MEA electrode showing the parameters used for statistical analysis. C)
Spike raster plot of spontaneously active cortical neurons on one MEA in artificial cerebrospinal fluid (aCSF) or 10 μM DMF. Each bar represents
one spike; electrode numbers are displayed on the vertical axis. The network exhibits correlated burst activity across several electrodes, which is
not altered from baseline by DMF. D) Treatment with 10 (top) or 100 (bottom) μM DMF for the indicated times does not change the number of
spikes and bursts per minute, the inter-burst interval, or the network activity using Cohen’s kappa as measure of synchrony of the activity on all
64 electrodes on the chip. Bar graphs of all experiments represent the means ± standard error of the mean (SEM) of three independent
experiments performed in triplicate. *P< 0.05, two-tailed Student’s t-test.
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pharmacologically or by incubation in cysteine-free
medium, which suggests enhanced glutathione recycling
through a mechanism that is as yet unknown.
We observed no upregulation of IL-4 and IL-5 but a
significant downregulation of TNFα, IL-2 and IL-17 in
DMF-treated anti-CD3-stimulated primary mouse sple-
nocytes from C57BL/6 mice, and additionally IL-4, IL-5,
IL-6, IL-17 and IFNγ downregulation in DMF-treated
splenocytes from SJL mice, which are a more immune-
responsive strain. It has to be kept in mind that in these
experiments we analyzed the direct effect of short-term,
low-concentration DMF treatment on unsorted spleno-
cytes without priming by antigen-presenting cells. A pre-
vious study reported that treatment with 70 μM DMF
augmented IL-4 production by CD4+ T lymphocytes
in vitro only when primed by dendritic cells but not
anti-CD3/28 antibodies alone indicating the requirement
of antigen-presenting cells for inducing a TH2 response
[8,19]. Our data suggest an additional direct effect of
DMF on immune cells which is different from its effect
during the priming of a T cell response.
Our experiments using media that were preconditioned
by DMF-pretreated neuronal cells indicate that both im-
mune and neuronal cells display increased intracellular
GSH after DMF treatment but only neuronal cells release
this glutathione into the extracellular space where it raises
the glutathione content of surrounding neuronal cells and
protects them from oxidative stress. The same medium
did not prevent unstimulated immune cells from dying
which suggests that the death of these cells is not primar-
ily mediated by oxidative stress or that they cannot take
up the glutathione. Interestingly, despite elevation of cel-
lular glutathione, DMF-pretreated splenocytes did not re-
lease glutathione and their medium did not increase the
glutathione content of neuronal cells. As cystine influ-
ences the enzymatic glutathione assay employed here by
disulfide exchange reactions with glutathione, the meas-
urement of glutathione discharged into the medium was
performed in cystine-free medium. Either splenocytes, in
contrast to HT22 cells, do not secrete GSH or they have a
heightened demand and use up the increased glutathione
during the 4 h incubation in cystine-free medium. Alter-
natively, they might lack the machinery necessary to re-
cycle glutathione.
Treatment with 10 or 100 μM DMF did not alter the
activity of primary cortical neurons plated on a multi-
electrode array indicating that it has no direct effects on
neuronal function in vitro.
Conclusions
In summary, our findings demonstrate that DMF at low
concentrations exerts protective effects on neuronal cells
and diminishes the production of TNF-α, IL-2, and IL-
17 in splenocytes from C57BL/6 mice and the
production of all cytokines measured in splenocytes
from SJL mice. Although higher concentrations of DMF
can cause cell death of primary splenocytes, this is prob-
ably not necessary for its immunomodulatory effect.
These observations might be relevant for understanding
the drug’s presumed mechanism of action as we assume
that the active metabolite MMF has similar effects that
merely need a longer time to develop.
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